However, rituximab may promote complement activation as an adverse reaction, which could explain the lack of response in some pwMG (89), including those with refractory MG who are double seronegative for anti-AChR and anti-MuSK antibodies (91). The gene discussed is MUSK; the disease is myasthenia gravis.